RyboDyn Maps Hidden Proteome to Uncover New Cancer Targets

The biotech sector has struggled with a diminishing supply of new biological targets, as current drug development pipelines frequently crowd around a handful of well-characterized proteins. While molecular design has advanced, the discovery of truly novel therapeutic axes has slowed significantly. RyboDyn’s research suggests this bottleneck persists because traditional tools rely on existing RNA annotations, effectively blinding researchers to protein variations that exist outside these known maps.

Using its proprietary platform, the San Diego-based company analyzed approximately 8.3 million 'dark' RNA isoforms, resulting in the creation of CypherAtlas. This database documents cryptic proteins—including transcription factors and membrane receptors—that are often tumor-specific. Among these findings is cYBX1, a cryptic isoform of the oncogenic driver YBX1. Unlike the canonical version, which has proven resistant to conventional drug approaches, cYBX1 offers a distinct molecular handle. In initial tests, antibodies targeting this specific cryptic protein demonstrated selective tumor cell elimination. By inverting the standard workflow to start with patient-derived data, RyboDyn aims to provide a new class of antibody therapeutics, with several candidates currently showing promise for lung, renal, and pancreatic cancers.